Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy

Area of Science:

• Oncology
• Dermatology
• Clinical Trials

Background:

• The standard of care for cutaneous melanoma has evolved significantly with advancements in targeted and immune therapies.
• Adjuvant therapy plays a crucial role in managing resected stage III/IV melanoma.

Purpose of the Study:

• To review pivotal randomized controlled trials that have shaped current adjuvant treatment standards for melanoma.
• To discuss the efficacy and approval of targeted therapies (BRAF inhibitors) and immunotherapies (CTLA-4, PD-1 inhibitors).
• To explore ongoing clinical trials and potential future therapeutic strategies.

Main Methods:

• Review of randomized controlled trials (RCTs) influencing melanoma treatment guidelines.
• Analysis of data from key studies supporting targeted and immune therapies.
• Discussion of trial designs, patient populations, and outcomes.

Main Results:

• BRAF and MEK inhibitors are approved for patients with BRAF-mutated melanoma.
• Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) or anti-programmed cell death-1 (PD-1) therapies are options for patients without BRAF mutations.
• These therapies have improved outcomes in adjuvant settings for resected advanced melanoma.

Conclusions:

• Current adjuvant treatment for resected stage III/IV melanoma is guided by specific trial data based on BRAF mutation status.
• Continued research and clinical trials are essential for further optimizing melanoma treatment.
• Future directions may involve novel combinations or personalized therapeutic approaches.